Navigation Links
Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
Date:6/3/2013

PLANTATION, Fla., June 3, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) announced today the award of a sub-contract from Emergent BioSolutions for GBI to conduct some early stage proof-of-concept feasibility process development to investigate concentrating AVA filtrate for storage before the downstream process for BioThrax® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the protection against anthrax disease.  Anthrax is a potentially deadly disease that is caused by the bacteria Bacillus anthracis.  While Anthrax does not spread directly from one infected animal or person to another, it is spread by endospores that are able to survive in harsh conditions for long periods of time, and those spores can lie dormant for years and possibly decades. When the spores are inhaled, ingested, or come into contact with a skin lesion on a host, they may germinate and multiply rapidly in both humans and animals. 

"We're excited about the opportunity to contribute our protein purification as well as processing experience and expertise which have been developed and refined over the last 20 years," noted Muctarr Sesay , PhD, Vice President of Process Development at GBI. "Our goal is to develop process parameters that are amenable to routine GMP production and large-scale manufacturing in an effort to contribute to the production of BioThrax at large scale."

Heidi Nielsen , Process Development Engineer for the Biodefense Division of Emergent BioSolutions said, "This phase of process development is critical to our project. We chose to work with Goodwin Biotechnology based on their Quality Systems and experience with large scale, GMP-compliant protein purification and processing."

About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.

For more information on the process development and GMP manufacturing of biologics, please contact Goodwin Biotechnology:
Robin McCallum
Business Development Manager
(954) 327-9656
RMcCallum@GoodwinBio.com


'/>"/>
SOURCE Goodwin Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
5. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
6. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Agricultural Biotechnology: Emerging Technologies and Global Markets
9. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
10. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
11. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... , Feb. 9, 2016  Jazz Pharmaceuticals plc ... report its 2015 fourth quarter and full year financial ... of the financial markets.  Company management will host a ... p.m. EST/9:30 p.m. GMT to discuss fourth quarter and ... and financial update and guidance for 2016 financial results. ...
Breaking Medicine Technology:
(Date:2/9/2016)... Altamonte Springs, FL (PRWEB) , ... February 09, ... ... nation’s leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It ... donations for each prescription referral received at our specialty pharmacy. , “Since ...
(Date:2/9/2016)... ... , ... The Journal of Pain Research has published the commentary ... As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention has ... patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the literature; ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... Maui, Hawaii (PRWEB) , ... February 09, 2016 , ... ... to Maui to lead a photographic adventure on the island, June 14-19, 2016, hosted ... Unforgettable Events series. , After a successful debut in 2015, the ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and developer of ... in the latest KLAS report, Population Health Management 2015: How Far Can Your Vendor ... population health management (PHM). The latest KLAS Report, leveraging over 200 user interviews, ...
Breaking Medicine News(10 mins):